Latest Buy Back Programs News

ClearView Wealth Limited delivered a robust second half in FY25, overcoming early claims volatility to restore margins and grow premiums. The company’s FY26 guidance signals confidence in continued growth, underpinned by a major technology platform migration and capital management initiatives.

ClearView Wealth Limited reported strong second-half growth in FY25, with underlying NPAT up 11% and life insurance margins rebounding. The company is poised for further expansion in FY26, backed by technology upgrades and strategic simplification.

ClearView Wealth Limited reported a solid 10% revenue increase for FY25 alongside a 126% jump in profit from continuing operations, yet net profit was tempered by losses from discontinued segments. The company paused its share buy-back program, signaling cautious capital management ahead.

Perseus Mining Limited has announced an on-market buy-back program to repurchase up to 40 million ordinary shares over the next year, signaling a strategic move in capital management.

Thorney Opportunities Ltd posted a sharp 76% decline in profit after tax for FY2025 yet declared a higher fully franked final dividend and reported growth in net tangible assets per share.

Shriro Holdings reported a 5.5% beat on EBITDA guidance despite a 13.6% revenue decline driven by strategic shifts in its importer model and distributor consolidation. The company signals optimism for FY26 with new product launches and a capital-light growth strategy.

L1 Long Short Fund Limited reported a net profit after tax of $99.52 million for FY2025, down 42% year-on-year, yet continues its steady dividend growth with a fully franked final dividend of 6.5 cents per share.

RAM Essential Services Property Fund reported solid FY25 results, highlighting portfolio growth, strategic capital recycling, and a clear transition towards a pure healthcare real estate focus.

Neuren Pharmaceuticals reported a robust half-year with an 88% increase in net profit, driven by rising royalties from DAYBUE™ sales and progress in its NNZ-2591 clinical program. The company also completed a $39.6 million share buy-back, underscoring confidence in its growth trajectory.

Mach7 Technologies reported a robust FY25 with 16% revenue growth and a strategic pivot towards customer-centric innovation, underpinned by leadership changes and a strong financial position.

Worley Limited posted robust full-year 2025 results, marked by strong revenue growth, margin expansion, and a significant increase in backlog, underpinned by major contract wins and sustainability progress.

Mach7 Technologies reported a 16% revenue increase and a near break-even adjusted EBITDA in FY25, setting the stage for a strategic overhaul expected next year.